Nazartinib (Egf816) In Patients With Treatment-Naive Egfr-Mutant Non-Small Cell Lung Cancer (Nsclc): Updated Phase Ii Results.

Daniel Shao-Weng Tan,Natasha B. Leighl,James Chih-Hsin Yang,Gregory J. Riely,Lecia Sequist,Ryo Toyozawa,Juergen Wolf,Enriqueta Felip,Sang-We Kim,Santiago Ponce Aix,Egbert F. Smit,Toyoaki Hida,Christian Grohe,Samson Ghebremariam,Leslie O'Sullivan-Djentuh,Riccardo Belli,Monica Giovannini,Dong-Wan Kim

Journal of Clinical Oncology（2020）

引用 3|浏览15

暂无评分

摘要

9574Background: Prior data from a phase I/II study showed durable responses, including efficacy in brain lesions, and a tolerable safety profile with nazartinib in treatment (tx)-naive patients (pt...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要